-
·
Latest Data on Newly Approved CLL Drug Pirtobrutinib Presented at ASH 2023
Latest Data on Newly Approved CLL Drug Pirtobrutinib Presented at ASH 2023 Top CLL doctors share their thoughts on pirtobrutinib Accelerated approval was granted to pirtobrutinib (JAYPIRCA, Eli Lilly and Company) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (CLL/SLL)…
-
·
Significant Disparity: Myeloma Real-World Results Show Striking Contrast with Clinical Trials
Worse Outcomes for Myeloma Patients in Real-World Results vs. Clinical Trials Multiple myeloma patient outcomes are strikingly different in the real-world versus controlled environments according to data presented at the ASH Conference 2023 (Abstract 541). In the real world, multiple myeloma patients demonstrated a 44% reduction in progression-free survival (PFS) and a 75% decrease in…
-
·
FDA Approves New Treatment Options for Relapsed/Refractory Multiple Myeloma Patients
FDA Approves New Treatment Option for Relapsed/Refractory Multiple Myeloma Patients
